Relay Therapeutics Inc (RLAY)
$13.53
$-0.13
(-0.95%)
As on 22-May-2026 16:00EDT
Market cap
$2,312 Mln
Revenue (TTM)
$11 Mln
P/E Ratio
--
P/B Ratio
3.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
191,586,165
6 Years Aggregate
CFO
$-816.97 Mln
EBITDA
$-972.60 Mln
Net Profit
$-1,257.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
| 59.9 | -19.5 | 55.5 | 373.1 | 8.9 | -14.8 | -- |
|
BSE Sensex
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
| 105.3 | -62.3 | -26.3 | -51.4 | -26.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Relay Therapeutics Inc (RLAY)
|
13.5 | 2,312.4 | 10.7 | -272.7 | -2,722.8 | -43.6 | -- | 3.6 |
| 75.0 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 76.9 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 50.2 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.0 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 68.3 | 8,152.3 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24.1 | 36.2 | |
| 299.5 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 517.3 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 432.8 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 343.6 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Relay Therapeutics Inc (RLAY)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The... company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 60 Hampshire Street, Cambridge, MA, United States, 02139 Read more
-
Co-Founder & Independent Chairman
Mr. Alexis A. Borisy A.M.
-
Co-Founder & Independent Chairman
Mr. Alexis A. Borisy A.M.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Relay Therapeutics Inc (RLAY)
What is the current share price of Relay Therapeutics Inc (RLAY) Today?
The share price of Relay Therapeutics Inc (RLAY) is $13.53 (NASDAQ) as of 22-May-2026 16:00 EDT. Relay Therapeutics Inc (RLAY) has given a return of 8.85% in the last 3 years.
What is the current PB & PE ratio of Relay Therapeutics Inc (RLAY)?
Since, TTM earnings of Relay Therapeutics Inc (RLAY) is negative, P/E ratio is not available.
The P/B ratio of Relay Therapeutics Inc (RLAY) is 3.60 times as on 20-May-2026, a 12 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.26
|
2.57
|
|
2024
|
-1.74
|
0.76
|
|
2023
|
-3.96
|
1.80
|
|
2022
|
-5.76
|
1.76
|
|
2021
|
-8.02
|
3.25
|
What is the 52 Week High and Low of Relay Therapeutics Inc (RLAY)?
The 52-week high and low of Relay Therapeutics Inc (RLAY) are Rs 17.32 and Rs 2.75 as of 23-May-2026.
What is the market cap of Relay Therapeutics Inc (RLAY)?
Relay Therapeutics Inc (RLAY) has a market capitalisation of $ 2,312 Mln as on 20-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Relay Therapeutics Inc (RLAY)?
Before investing in Relay Therapeutics Inc (RLAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.